Résilience - COVID-19 - Résilience - Coronavirus disease 2019

Allergy to COVID-19 Vaccines – ALLCOV

Submission summary

In the context of the COVID-19 pandemic, vaccination plays a major role to reduce the virus circulation and the number of severe cases. However, the risk of severe allergic reaction, or anaphylaxis, reduce the access to vaccination. To date, the pursuit of vaccination is contraindicated for people who presented with a reaction to the first dose, and patients with drug allergy history are referred to a specialized team for evaluation, which delays considerably vaccination. This is damageable in terms of individual protection but could also facilitate variants emergence due to incomplete immunization. To address these issues, a better knowledge of these reactions is urgently needed.
Allergy to vaccines in most cases attributed to excipients. Several immunological and non-immunological pathways have been described. Currently, there is no documentation of the mechanism responsible for the severe reactions observed in COVID-19- vaccinated patients and the potential allergens are not known.
The present project aims to take advantage of a triple clinical, biological, and chemical expertise to determine the mechanisms involved in severe reaction to COVID-19 vaccines and to identify the allergens responsible for such reactions. We will analyze cell activation and potential mediators in blood samples taken during the reaction. In the context of a post-reaction allergy evaluation, we will identify the allergens with a combination of skin testing and ex vivo restimulations. Lastly, we will develop innovative in vitro diagnostic tests to detect allergen-specific IgE and memory T cells. This knowledge will allow us to propose a safe alternative for at-risk patients and to risk-stratify patients with allergic background.
This multidisciplinary project will contribute to epidemic control by allowing patients with either an allergic background or a reaction to the first dose to have access to full vaccination and immunity

Project coordination

Luc de Chaisemartin (INSERM U1222 "Antibodies in Therapy and Pathology")

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.

Partner

INSERM U1222 "Antibodies in Therapy and Pathology"
UPSaclay / BioCIS Université Paris-Saclay / Biomolécules : Conception, Isolement, Synthèse
Service de Dermatologie et Allergologie, Hôpital Tenon APHP

Help of the ANR 79,220 euros
Beginning and duration of the scientific project: May 2021 - 9 Months

Useful links

Explorez notre base de projets financés

 

 

ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter